Cargando…
Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival
BACKGROUND: The aim of this study was to correlate T1-weighted dynamic contrast-enhanced MRI- (DCE-MRI-) derived perfusion parameters with overall survival of recurrent high-grade glioma patients who received neural stem cell- (NSC-) mediated enzyme/prodrug gene therapy. METHODS: A total of 12 patie...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872616/ https://www.ncbi.nlm.nih.gov/pubmed/29731779 http://dx.doi.org/10.1155/2018/5312426 |
_version_ | 1783309874674794496 |
---|---|
author | Sahoo, Prativa Frankel, Paul Ressler, Julie Gutova, Margarita Annala, Alexander J. Badie, Behnam Portnow, Jana Aboody, Karen S. D'Apuzzo, Massimo Rockne, Russell C. |
author_facet | Sahoo, Prativa Frankel, Paul Ressler, Julie Gutova, Margarita Annala, Alexander J. Badie, Behnam Portnow, Jana Aboody, Karen S. D'Apuzzo, Massimo Rockne, Russell C. |
author_sort | Sahoo, Prativa |
collection | PubMed |
description | BACKGROUND: The aim of this study was to correlate T1-weighted dynamic contrast-enhanced MRI- (DCE-MRI-) derived perfusion parameters with overall survival of recurrent high-grade glioma patients who received neural stem cell- (NSC-) mediated enzyme/prodrug gene therapy. METHODS: A total of 12 patients were included in this retrospective study. All patients were enrolled in a first-in-human study (NCT01172964) of NSC-mediated therapy for recurrent high-grade glioma. DCE-MRI data from all patients were collected and analyzed at three time points: MRI#1—day 1 postsurgery/treatment, MRI#2— day 7 ± 3 posttreatment, and MRI#3—one-month follow-up. Plasma volume (V (p)), permeability (K (tr)), and leakage (λ (tr)) perfusion parameters were calculated by fitting a pharmacokinetic model to the DCE-MRI data. The contrast-enhancing (CE) volume was measured from the last dynamic phase acquired in the DCE sequence. Perfusion parameters and CE at each MRI time point were recorded along with their relative change between MRI#2 and MRI#3 (Δ(32)). Cox regression was used to analyze patient survival. RESULTS: At MRI#1 and at MRI#3, none of the parameters showed a significant correlation with overall survival (OS). However, at MRI#2, CE and λ (tr) were significantly associated with OS (p < 0.05). The relative λ (tr) and V (p) from timepoint 2 to timepoint 3 (Δ(32) λ (tr) and Δ(32) V (p)) were each associated with a higher hazard ratio (p < 0.05). All parameters were highly correlated, resulting in a multivariate model for OS including only CE at MRI#2 and Δ(32) V (p), with an R (2) of 0.89. CONCLUSION: The change in perfusion parameter values from 1 week to 1 month following NSC-mediated therapy combined with contrast-enhancing volume may be a useful biomarker to predict overall survival in patients with recurrent high-grade glioma. |
format | Online Article Text |
id | pubmed-5872616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58726162018-05-06 Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival Sahoo, Prativa Frankel, Paul Ressler, Julie Gutova, Margarita Annala, Alexander J. Badie, Behnam Portnow, Jana Aboody, Karen S. D'Apuzzo, Massimo Rockne, Russell C. Stem Cells Int Research Article BACKGROUND: The aim of this study was to correlate T1-weighted dynamic contrast-enhanced MRI- (DCE-MRI-) derived perfusion parameters with overall survival of recurrent high-grade glioma patients who received neural stem cell- (NSC-) mediated enzyme/prodrug gene therapy. METHODS: A total of 12 patients were included in this retrospective study. All patients were enrolled in a first-in-human study (NCT01172964) of NSC-mediated therapy for recurrent high-grade glioma. DCE-MRI data from all patients were collected and analyzed at three time points: MRI#1—day 1 postsurgery/treatment, MRI#2— day 7 ± 3 posttreatment, and MRI#3—one-month follow-up. Plasma volume (V (p)), permeability (K (tr)), and leakage (λ (tr)) perfusion parameters were calculated by fitting a pharmacokinetic model to the DCE-MRI data. The contrast-enhancing (CE) volume was measured from the last dynamic phase acquired in the DCE sequence. Perfusion parameters and CE at each MRI time point were recorded along with their relative change between MRI#2 and MRI#3 (Δ(32)). Cox regression was used to analyze patient survival. RESULTS: At MRI#1 and at MRI#3, none of the parameters showed a significant correlation with overall survival (OS). However, at MRI#2, CE and λ (tr) were significantly associated with OS (p < 0.05). The relative λ (tr) and V (p) from timepoint 2 to timepoint 3 (Δ(32) λ (tr) and Δ(32) V (p)) were each associated with a higher hazard ratio (p < 0.05). All parameters were highly correlated, resulting in a multivariate model for OS including only CE at MRI#2 and Δ(32) V (p), with an R (2) of 0.89. CONCLUSION: The change in perfusion parameter values from 1 week to 1 month following NSC-mediated therapy combined with contrast-enhancing volume may be a useful biomarker to predict overall survival in patients with recurrent high-grade glioma. Hindawi 2018-03-14 /pmc/articles/PMC5872616/ /pubmed/29731779 http://dx.doi.org/10.1155/2018/5312426 Text en Copyright © 2018 Prativa Sahoo et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sahoo, Prativa Frankel, Paul Ressler, Julie Gutova, Margarita Annala, Alexander J. Badie, Behnam Portnow, Jana Aboody, Karen S. D'Apuzzo, Massimo Rockne, Russell C. Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival |
title | Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival |
title_full | Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival |
title_fullStr | Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival |
title_full_unstemmed | Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival |
title_short | Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival |
title_sort | early changes in tumor perfusion from t1-weighted dynamic contrast-enhanced mri following neural stem cell-mediated therapy of recurrent high-grade glioma correlate with overall survival |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872616/ https://www.ncbi.nlm.nih.gov/pubmed/29731779 http://dx.doi.org/10.1155/2018/5312426 |
work_keys_str_mv | AT sahooprativa earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT frankelpaul earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT resslerjulie earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT gutovamargarita earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT annalaalexanderj earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT badiebehnam earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT portnowjana earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT aboodykarens earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT dapuzzomassimo earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival AT rocknerussellc earlychangesintumorperfusionfromt1weighteddynamiccontrastenhancedmrifollowingneuralstemcellmediatedtherapyofrecurrenthighgradegliomacorrelatewithoverallsurvival |